Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma

Journal of Controlled Release

Volumn 145, Issue 1, 2010, Pages 66-73

  Loi, Monica ^a   Marchiò, Serena ^b,c   Becherini, Pamela ^a   Di Paolo, Daniela ^a   Soster, Marco ^b   Curnis, Flavio ^d   Brignole, Chiara ^a   Pagnan, Gabriella ^a   Perri, Patrizia ^a   Caffa, Irene ^a   Longhi, Renato ^e   Nico, Beatrice ^f   Bussolino, Federico ^b,c   Gambini, Claudio ^a   Ribatti, Domenico ^f   Cilli, Michele ^g   Arap, Wadih ^h   Pasqualini, Renata ^h   Allen, Theresa M ⁱ   Corti, Angelo ^d   Ponzoni, Mirco ^a   Pastorino, Fabio ^a   more..

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c APAvadis Biotechnologies srl   (Italy)

^d San Raf faele Institute   (Italy)

^e CNR   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Combination therapy; Neuroblastoma; Vascular disrupting agent; Vasculature targeted liposomes

Indexed keywords

COMBINATION THERAPY; NEUROBLASTOMA; NEUROBLASTOMAS; VASCULATURE; VASCULATURE-TARGETED LIPOSOMES;

ANIMALS; BEARINGS (STRUCTURAL); CELL DEATH; CHEMOTHERAPY; ENDOTHELIAL CELLS; ENZYME INHIBITION; LIGANDS; LIPOSOMES; PEPTIDES; PHOSPHOLIPIDS; SELF ASSEMBLY;

TUMORS;

DOXORUBICIN; GLUTAMYL AMINOPEPTIDASE; LIPOSOME; MICROSOMAL AMINOPEPTIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIFESPAN; MOUSE; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PERICYTE; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR VASCULARIZATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD13; DOXORUBICIN; DRUG COMPOUNDING; ENDOTHELIAL CELLS; FEMALE; GLUTAMYL AMINOPEPTIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LIPOSOMES; MICE; MICE, NUDE; NEUROBLASTOMA; PEPTIDES; PROTEIN BINDING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953357460     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.03.015     Document Type: Article

References (49)

1. Brodeur G.M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 2003, 3(3):203-216.
2. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369(9579):2106-2120.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1(1):27-31.
4. Giavazzi R., Bani M.R., Taraboletti G. Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. Cancer Metastasis Rev. 2007, 26(3-4):481-488.
5. Siemann D.W., Chaplin D.J., Horsman M.R. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004, 100(12):2491-2499.
6. Chaplin D.J., Horsman M.R., Siemann D.W. Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs 2006, 7(6):522-528.
7. Rehman F., Rustin G. ASA404: update on drug development. Expert Opin. Investig. Drugs 2008, 17(10):1547-1551.
8. Jain R.K. Molecular regulation of vessel maturation. Nat. Med. 2003, 9(6):685-693.
9. Gaya A.M., Rustin G.J. Vascular disrupting agents: a new class of drug in cancer therapy. Clin. Oncol. (R. Coll. Radiol.) 2005, 17(4):277-290.
10. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 2004, 10(2):415-427.
11. Pastorino F., Di Paolo D., Piccardi F., Nico B., Ribatti D., Daga A., Baio G., Neumaier C.E., Brignole C., Loi M., Marimpietri D., Pagnan G., Cilli M., Lepekhin E.A., Garde S.V., Longhi R., Corti A., Allen T.M., Wu J.J., Ponzoni M. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin. Cancer Res. 2008, 14(22):7320-7329.
12. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2(10):750-763.
13. Sapra P., Allen T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 2002, 62(24):7190-7194.
14. Simone E., Ding B.S., Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res. 2009, 335(1):283-300.
15. Cai W., Chen X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49(Suppl 2):113S-128S.
16. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296(5577):2404-2407.
17. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., Wrasidlo W., Cheresh D.A. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc. Natl Acad. Sci. USA 2008, 105(27):9343-9348.
18. Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23(5):939-952.
19. Marchio S., Lahdenranta J., Schlingemann R.O., Valdembri D., Wesseling P., Arap M.A., Hajitou A., Ozawa M.G., Trepel M., Giordano R.J., Nanus D.M., Dijkman H.B., Oosterwijk E., Sidman R.L., Cooper M.D., Bussolino F., Pasqualini R., Arap W. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004, 5(2):151-162.
20. Schlingemann R.O., Oosterwijk E., Wesseling P., Rietveld F.J., Ruiter D.J. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J. Pathol. 1996, 179(4):436-442.
21. Sergeeva A., Kolonin M.G., Molldrem J.J., Pasqualini R., Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv. Drug Deliv. Rev. 2006, 58(15):1622-1654.
22. Zurita A.J., Arap W., Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J. Control. Release 2003, 91(1-2):183-186.
23. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60(3):722-727.
24. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003, 63(21):7400-7409.
25. Pastorino F., Marimpietri D., Brignole C., Di Paolo D., Pagnan G., Daga A., Piccardi F., Cilli M., Allen T.M., Ponzoni M. Ligand-targeted liposomal therapies of neuroblastoma. Curr. Med. Chem. 2007, 14(29):3070-3078.
26. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 2000, 18(11):1185-1190.
27. Colombo G., Curnis F., De Mori G.M., Gasparri A., Longoni C., Sacchi A., Longhi R., Corti A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem. 2002, 277(49):47891-47897.
28. Di Matteo P., Curnis F., Longhi R., Colombo G., Sacchi A., Crippa L., Protti M.P., Ponzoni M., Toma S., Corti A. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol. Immunol. 2006, 43(10):1509-1518.
29. Moase E.H., Qi W., Ishida T., Gabos Z., Longenecker B.M., Zimmermann G.L., Ding L., Krantz M., Allen T.M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta 2001, 1510(1-2):43-55.
30. Pastorino F., Brignole C., Marimpietri D., Sapra P., Moase E.H., Allen T.M., Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 2003, 63(1):86-92.
31. Curnis F., Sacchi A., Gasparri A., Longhi R., Bachi A., Doglioni C., Bordignon C., Traversari C., Rizzardi G.P., Corti A. Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res. 2008, 68(17):7073-7082.
32. Ponzoni M., Bocca P., Chiesa V., Decensi A., Pistoia V., Raffaghello L., Rozzo C., Montaldo P.G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res. 1995, 55(4):853-861.
33. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 2006, 66(20):10073-10082.
34. Cao Q., Li Z.B., Chen K., Wu Z., He L., Neamati N., Chen X. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(8):1489-1498.
35. Kolonin M.G., Sun J., Do K.A., Vidal C.I., Ji Y., Baggerly K.A., Pasqualini R., Arap W. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB.J 2006, 20(7):979-981.
36. Holle L., Song W., Hicks L., Holle E., Holmes L., Wei Y., Li J., Wagner T., Yu X. In vitro targeted killing of human endothelial cells by co-incubation of human serum and NGR peptide conjugated human albumin protein bearing alpha (1-3) galactose epitopes. Oncol. Rep. 2004, 11(3):613-616.
37. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390(6658):404-407.
38. Shaked Y., Ciarrocchi A., Franco M., Lee C.R., Man S., Cheung A.M., Hicklin D.J., Chaplin D., Foster F.S., Benezra R., Kerbel R.S. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313(5794):1785-1787.
39. Kerbel R.S. Tumor angiogenesis. N. Engl. J. Med. 2008, 358(19):2039-2049.
40. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 2008, 8(8):592-603.
41. Allen T.M., Cullis P.R. Drug delivery systems: entering the mainstream. Science 2004, 303(5665):1818-1822.
42. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111(9):1287-1295.
43. Shaked Y., Henke E., Roodhart J.M., Mancuso P., Langenberg M.H., Colleoni M., Daenen L.G., Man S., Xu P., Emmenegger U., Tang T., Zhu Z., Witte L., Strieter R.M., Bertolini F., Voest E.E., Benezra R., Kerbel R.S. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 2008, 14(3):263-273.
44. Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63(15):4342-4346.
45. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 2007, 99(19):1441-1454.
46. van der Veen A.H., de Wilt J.H., Eggermont A.M., van Tiel S.T., Seynhaeve A.L., ten Hagen T.L. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br. J. Cancer 2000, 82(4):973-980.
47. Brunstein F., Hoving S., Seynhaeve A.L., van Tiel S.T., Guetens G., de Bruijn E.A., Eggermont A.M., ten Hagen T.L. Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. J. Natl Cancer Inst. 2004, 96(21):1603-1610.
48. Hoving S., Brunstein F., de Wiel-Ambagtsheer G.aan, van Tiel S.T., de Boeck G., de Bruijn E.A., Eggermont A.M., ten Hagen T.L. Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats. Cancer Res. 2005, 65(10):4300-4308.
49. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279(5349):377-380.